Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin for anti-bornavirus antibody–positive, treatment-resistant neuropsychiatric symptoms
jRCTs051180130Completed
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ribavirin in schizophrenia, Schizophrenia Spectrum Disorders (SSD), affective disorder and 2 more. Primary endpoint: Change in individually defined target symptoms. Started Nov 2020; status: completed.
02
Drugs
ribavirin
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)affective disorderDementiaTreatment-resistant neuropsychiatric disorder (TRND)
Beyond the preview
Go deeper on jRCTs051180130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180130.